IDWeek

The Latest

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

By Sony Salzman

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

By Barbara Jungwirth

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

By Mark Mascolini

Ibalizumab Effective Against Drug-Resistant HIV in 48-Week Data

The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.

By Sony Salzman

How Can We Keep People With HIV in Care? New Research Offers Insights

Two studies presented at IDWeek 2017 looked at patient and provider issues that impact retention in care and offered new insights that might help end disparities in the HIV care continuum.

By Sony Salzman

Low Dietary Calcium Tied to Low BMD With HCV but Not HIV

Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.

By Mark Mascolini

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial

A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.

By Mark Mascolini

In a Large HIV Group, Only 36% of Those Needing Statins Received Statins

The majority of HIV-positive people with a statin indication by current guidelines are not receiving a statin, according to an analysis at a St. Louis HIV clinic.

By Mark Mascolini

New HIV Rate Similar Above and Below Age 45 in 86,836-Person U.S. Study

In the years 2011-2013 people 45 or older acquired HIV infection at a frequency similar to that of younger people in New York City, San Francisco, and North Carolina.

By Mark Mascolini

Better Use of Electronic Health Records Might Help Close HIV Testing Gap in U.S.

Jason Zucker, M.D., discusses how we can use computer algorithms to help ensure that undiagnosed people with HIV are tested, thus increasing the likelihood of them moving forward on the HIV care cascade.

By Sony Salzman